Stifel raised the firm’s price target on Becton Dickinson to $280 from $270 and keeps a Buy rating on the shares. The firm is updating its Critical Care acquisition pro forma estimates, telling investors that the accretion potential is “a bit better than we initially thought.” The firm now thinks Critical Care will bring better margins and stronger EPS accretion to Becton than consensus is currently-contemplating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- BD Board Declares Dividend
- BD experiencing reduced availability of BD BACTEC vials from supplier
- Becton Dickinson price target lowered to $255 from $260 at Citi
- Becton Dickinson added to ‘Tactical Outperform’ list, target trimmed at Evercore
- 3 Best Healthcare Stocks to Buy in June 2024, as per Analysts